Mtss1 is located within chromosomal region 8q23-24, which is one of the three most commonly amplified regions in head and neck squamous cell carcinoma (HNSCC). Mtss1 is lost in metastatic cells, but confusingly is commonly overexpressed in primary tumors. Here we address possible reasons why Mtss1 is positively selected for in primary tumors. We find that Mtss1 enhances the localization of the epidermal growth factor (EGF) receptor to the plasma membrane, prolonging EGF signaling and resulting in enhanced proliferation in HNSCC. Depletion of Mtss1 results in decreased EGF receptor levels and decreased phosphorylation of Erk1/2 and Akt. However, when cells are at high density and adherent to each other, analogous to conditions in a solid tumor, Mtss1 does not confer any growth advantage, either in basal conditions or following EGF stimulation. This could indicate why Mtss1 might be lost in metastases, but preserved in early primary tumors. This is supported by an organotypic assay showing that Mtss1-expressing cells display a less proliferative more epithelial-like morphology on top of a collagen matrix. Furthermore, xenograft tumors expressing Mtss1 initially grow more rapidly, but later show less proliferation and more differentiation. Mtss1 positively modulates EGF signaling at low cell densities to promote proliferation and, therefore, may be beneficial for the early stages of primary HNSCC tumor growth. However, at high cell densities, Mtss1 impacts negatively on EGF signaling and this suggests why it inhibits metastasis.
Introduction
Regulation of growth factor signaling through receptor tyrosine kinases (RTK) is often disrupted in the development of cancer, leading to uncontrolled proliferation, survival and metastasis. In head and neck squamous cell carcinoma (HNSCC), cells undergo numerous chromosomal deletions and amplifications that result in the loss of important cellular regulatory proteins and amplification of oncogenic proteins (Kelley et al., 2008; Cooper and Cohen, 2009 ). This often results in amplification of the epidermal growth factor receptor (EGFR) and misregulation of EGF signaling, internalization and degradation, making EGFR a strong target for chemotherapeutic strategies (Mosesson et al., 2008; Cooper and Cohen, 2009 ). Therefore, understanding how signaling through EGFR is altered is of great interest and will be useful for the diagnosis and treatment of HNSCC.
EGF binding to the EGFR results in internalization via clathrin-dependent and -independent endocytosis routes (Sigismund et al., 2008; Goh et al., 2010) . Once endocytosed, vesicles are trafficked to early endosomes for cargo sorting, where the EGFR is either targeted for degradation in lysosomes or recycled back to the plasma membrane. During this translocation from the plasma membrane to the endosomal system, the EGFR still signals to its downstream targets. Switching off EGFR signaling by degrading the receptor requires its targeting to lysosomes by receptor ubiquitination (Mosesson et al., 2008; Sorkin and Goh, 2009 ). Critically, the disruption of this endocytic process in cancer results in reduced lysosomal targeting of receptors for degradation and prolonged signaling of classical kinase pathways such as Erk and Akt, and leads to proliferation, increased survival and invasion.
During tumor progression, cancer cells undergo changes, including increased RTK signaling, that result in the ability to break off from the tumor mass, invade and metastasize to distant sites of the body (Mosesson et al., 2008) . This process is known as epithelial-tomesenchymal transition and involves the loss or mutation of the E-cadherin receptor, the major cadherin found in the epithelia (Cheng et al., 2007; Yang et al., 2008; Gan et al., 2010) . Loss of E-cadherin results in the ability of cancer cells to break away from the tumor (Cheng et al., 2007; Yang et al., 2008) . In addition to the mechanical role of physically anchoring cells in an epithelium, E-cadherin cell-cell junctions are also involved in negatively regulating RTK signaling (Qian et al., 2004; Bremm et al., 2008) .
Mtss1 was originally identified as 'missing in metastasis' (MIM-B) in bladder cancer (Lee et al., 2002) , but also resides on 8q23-24, which is frequently amplified in HNSCC (Kelley et al., 2008) . Loss of Mtss1 protein expression in hepatocellular carcinoma, breast and gastric cancers is also associated with metastasis and correlates with poor patient survival (Callahan et al., 2004; Loberg et al., 2005; Parr and Jiang, 2009; Liu et al., 2010) . Interestingly, in hepatocellular carcinoma, Mtss1 is upregulated at the early stages of disease, but missing in the later metastatic stages (Ma et al., 2007) . Similarly, Mtss1 has also been identified as a sonic hedgehog-responsive gene (BEG4) in the development of basal cell carcinoma that, in concert with the transcription factor Gli, drives the proliferation and invasion of epidermal cells in regenerated skin assays (Callahan et al., 2004) . Why Mtss1 protein is overexpressed during the early development of cancer and then lost during the later metastatic stages is unclear.
Mtss1 is a scaffolding protein linking the actin cytoskeleton and the plasma membrane (Mattila et al., 2003 (Mattila et al., , 2007 Woodings et al., 2003; Bompard et al., 2005; Gonzalez-Quevedo et al., 2005; Lin et al., 2005; Lee et al., 2007) . Through this ability, Mtss1 antagonizes EGFR endocytosis during Drosophila oocyte border cell migration (Quinones et al., 2010) and regulates signaling during ciliogenesis (Bershteyn et al., 2010) , suggesting that Mtss1 might influence EGFR signaling in cancer. We therefore decided to investigate the role of Mtss1 expression in HNSCC. We find that Mtss1 is differentially expressed in a panel of HNSCC cell lines and is upregulated in HNSCC primary tumor samples. We show that enhancing Mtss1 expression in HeLa or Scc9 cells, an HNSCC cell line with low expression of Mtss1, results in enhanced localization of the EGFR to the plasma membrane, enhancing EGF signaling and proliferation. We further show that depletion of Mtss1 in three HNSCC cell lines reduces the expression of the EGFR and decreases Erk1/2 and Akt phosphorylation. Finally, we find that Mtss1 enhances cell densitydependent inhibition of EGF signaling, which requires cell-cell junctions. In organotypic invasion and mouse xenograft assays, this results in reduced proliferation. These data suggest that Mtss1 regulates the EGFR and can enhance proliferation of early-stage HNSCC cells/ tumors. However, our data also suggest that Mtss1 inhibits EGFR signaling at high cell densities. This observation may explain why Mtss1 is overexpressed in early primary tumor development, but is lost as disease progresses.
Results

Mtss1 is overexpressed in HNSCC cell lines and primary tumors
Mtss1 is found within an amplicon on chromosome 8q23-24 that is commonly amplified in HNSCC (Kelley et al., 2008) . To confirm this observation, we analyzed Mtss1 expression in a microarray data set of primary HNSCC tumors (Figures 1a and b; Thurlow et al., 2010) . We found Mtss1 to be significantly overexpressed, by 1.3-1.5-fold, in primary HNSCC tumor samples (three out of four probes from 71 HNSCC tumors versus 14 normal tissue samples). We find that in a panel of HNSCC cell lines, Mtss1 protein expression is approximately 2.5-fold higher in FaDu and Detroit 562 HNSCC cell lines than Scc9, Scc15 or Scc25 (Figure 1c ). We began by stably expressing Mtss1-GFP in Scc9 cells to approximately threefold over the endogenous level ( Figure 1d ) and comparable to that seen in FaDu and Detroit 562 cell lines.
Mtss1 alters the cellular localization of the EGFR and increases signaling in HNSCC Mtss1 has previously been shown to regulate the surface dynamics of EGFR in Drosophila and mouse fibroblasts (Quinones et al., 2010) . Therefore, we investigated whether Mtss1 expression could influence EGFR dynamics in HNSCC cells. By FACS analysis, Mtss1-GFP-expressing Scc9 cells had more cell surface EGFR compared to Scc9 (c) Mean relative EGFR surface intensity in high-and low-expressing Mtss1-GFP Scc9 cells ±s.e.m. is shown from three independent experiments. (d) Starved cells were stimulated with 25 ng/ml EGF for 0, 10 and 30 min, and then proteins on the cell surface were biotinylated. Surface and total lysates were probed for EGFR and tubulin. Mean intensity of western blot bands ( ± s.d.) of surface EGFR from three independent experiments relative to Scc9 cells is shown in the graph to the right. For (c and d), *Po0.05 and **Po0.01. cells alone (Figure 2a ). Analysis of high and low Mtss1-GFP-expressing Scc9 cells revealed that high Mtss1-GFP-expressing cells displayed significantly more EGFR on the cell surface than low Mtss1-GFP-expressing cells (Figures 2b and c) .
To compare EGFR internalization rates in high and low Mtss1-expressing cells, we biotinylated the cell surface proteins during a short time course of EGF stimulation and measured the surface expression versus the total EGFR expression ( Figure 2d ). In Scc9 cells, EGFR internalization commenced within minutes of EGF simulation and by 30 min approximately 50% of the initial EGFR had been internalized. Mtss1-expressing cells displayed approximately 1.4-fold increased surface expression of the EGFR at t ¼ 0 ( Figure 2d ). Upon EGF stimulation, surface EGFR levels decreased at a rate similar to controls ( Figure 2d ). We did not observe any change in surface expression of E-cadherin under these conditions (Supplementary Figure S1 ). Thus, the increased surface level of EGFR in high Mtss1-expressing cells is unlikely to be due to a decrease in ligand-induced internalization rates.
Mtss1 enhances EGF signaling in HNSCC cell lines
We asked whether increased surface levels of EGFR affected EGFR signaling in Mtss1-GFP-expressing Scc9 cells (Figures 3a and b) . EGF stimulation induced a rapid phosphorylation of the EGFR over a 45-min period with markedly more sustained EGFR phosphorylation in Mtss1-GFP-expressing Scc9 cells ( Figure 3a ). Following EGF stimulation, Erk1/2 phosphorylation in Scc9 cells peaked at 10 min and gradually decayed over the 240 min. High Mtss1-expressing cells showed increased Erk1/2 phosphorylation by 10 min after EGF Figure 3 Mtss1 enhances EGF signaling in HNSCC cell lines. (a) EGFR was immunoprecipitated following EGF stimulation for the indicated times and blotted for total EGFR and tyrosine phosphorylation (4G10). (b) Western blot for phosphorylated Erk1/2 following stimulation with 25 ng/ml EGF. Numbers under blots show relative Erk1/2 phosphorylation compared to Scc9 cells stimulated at 10 min. Western blot is representative of at least three experiments. (c) MTT growth assay. Cells were grown in the presence of 10 ng/ml EGF for the indicated times. Mean optical density (560 nm) is shown ±s.e.m. from four independent experiments. (d) Colony-forming assay. In total, 2000 cells per well of a six-well plate were cultured for 5 days. Area of colony growth was calculated using the ImageJ software and is representative of three experiments performed in triplicate. For (c and d), *Po0.05 and ***Po0.001. stimulation and a subsequent slower decay was observed. In support of these experiments in Scc9 cells, we find that high expression of Mtss1 in HeLa cells also drives a decrease in EGFR degradation following ligand stimulation and a concurrent increase in Erk1/2 phosphorylation (Supplementary Figure S2 ). Erk1/2 activity controls cell proliferation and high Mtss1 expression resulted in increased proliferation over 5 days in culture of Scc9 cells in the presence of 10 ng/ml EGF in an MTT (dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) proliferation assay ( Figure 3c ). Finally, we determined the effect of Mtss1 expression on the ability of Scc9 cells to form and grow as colonies in a clonogenic assay. Mtss1 expression in Scc9 cells gave a significant growth advantage over Scc9 cells alone (Figure 3d ), demonstrating that Mtss1 can increase proliferation.
Depletion of Mtss1 reduces EGFR expression and downstream signaling in HNSCC
FaDu and Detroit 562 HNSCC cell lines, which have high endogenous Mtss1 (Figure 1c ), exhibit high aberrant EGFR signaling (Timpson et al., 2005 (Timpson et al., , 2007 . We therefore depleted Mtss1 to examine the connection with EGFR signaling (Figure 4 ). Depletion of Mtss1 in FaDu and Detroit 562 HNSCC cell lines reduced the basal levels of EGFR protein (Figure 4a ). Erk1/2 and Akt phosphorylation were also reduced ( Figure 4a ). Interestingly, Scc9 cells responded similarly when treated with Mtss1 siRNA, displaying reduced EGFR protein and basal Erk1/2 and Akt phosphorylation (Figures 4a and b ).
Mtss1 expression regulates HNSCC proliferation in organotypic invasion and mouse xenograft assays Mtss1 has been proposed as a suppressor of metastasis; however, our observations that Mtss1 can enhance EGF signaling seem puzzling in light of this. We therefore investigated how Mtss1 affected the ability of Scc9 cells to grow and invade in an organotypic invasion assay ( Figure 5 ). After 10 days of growth, we observed an increased epithelial-like morphology of Mtss1-GFPexpressing cells on the top of the collagen matrix ( Figure 5a , enlarged pictures, panels 1 and 3). However, we observed no significant difference in the invasion of Scc9 cells regardless of Mtss1-GFP levels (Figures 5a  and b ).
However, we noticed that the high Mtss1-expressing cells formed larger colonies of invaded cells in the collagen matrix (Figures 5a (panels 2 and 4) and c). As we have shown that Mtss1 expression increases proliferation through EGF signaling in Scc9 cells (Figure 3) , we labeled the organotypic assays for Ki67, a marker of proliferation. For the colonies of invaded cells, controls and high Mtss1-expressing cells showed no difference (Figures 5d-f ), but high Mtss1-expressing cells displayed significantly less Ki67 staining in the epithelial-like layer on top of the collagen (Figures 5d-f ). The Mtss1-expressing cells on top of the collagen also frequently formed more orderly layers than the Scc9 cells and appeared more epithelial. These results suggested that the cell density might affect EGF signaling and thus proliferation induced by Mtss1. To determine the effect of high Mtss1 on Scc9 tumor formation in vivo, we used a subcutaneous transplant model in nude mice ( Figure 6 ). Mtss1-expressing Scc9 tumors grew faster over the initial 12-day period following implantation (Figure 6a) ; however, by 20 days after injection, we observed no significant difference, suggesting that Mtss1 conferred a growth advantage during the initial stages of tumor formation, but not at high densities as tumors grew ( Figure 5 ). Immunohistochemical analysis revealed that Mtss1 expressing tumors (five of five) had undergone a large degree of keratinization (Figure 6b ), whereas only (two of six) Scc9 tumors showed keratinization. Ki67 labeling revealed that there was a significant reduction in proliferation in Mtss1 tumors compared to Scc9 alone (Figure 6c ), confirming our previous observation in the organotypic assay ( Figure 5 ). Thus, in vivo high Mtss1 expression may confer a growth advantage at low densities during tumor initiation, but once a tumor is established, high Mtss1 rather leads to less proliferation in favor of differentiation in HNSCC tumors.
Mtss1-induced signaling is dependent on cell-cell junctions
Increasing cell density reduces RTK signaling through E-cadherin cell-cell junctions (Qian et al., 2004; Bremm et al., 2008) , so we investigated whether Mtss1 expression increased susceptibility to cell density-induced inhibition of RTK signaling. Cells were grown to confluence over 1-3 days and lysates were harvested each day to examine the activation of Erk1/2 and Akt ( Supplementary  Figures S3A and B) . At days 1 and 2, Erk1/2 phosphorylation was significantly higher in Mtss1-expressing cells than Scc9, but by day 3 when cells were confluent, the difference was not significant ( Supplementary Figures S3A  and B ). Both Erk1/2 and Akt phosphorylation decreased in Mtss1-expressing and control cells as confluence increased ( Supplementary Figures S3A and B) .
To test whether cell-cell junctions contributed to this change in EGF signaling, we analyzed EGF signaling in confluent cells with and without cell-cell junctions (Figure 7) . Cell-cell junctions were disassembled by starving cells overnight in a low [Ca 2 þ ] medium (Qian et al., 2004) or by prior treatment with E-cadherin siRNA (Supplementary Figure S3C ). In the presence of cell-cell junctions, 10 min of EGF stimulation induced a greater increase in EGFR phosphorylation in Scc9 cells compared to those expressing Mtss1 (Figure 7a ). In the absence of cell-cell junctions, more EGFR phosphorylation was observed in Mtss1-expressing cells, supporting the hypothesis that in confluent cells making junctions high Mtss1 has a growth inhibitory effect, while at low densities or in the absence of junctions, it can promote EGFR signaling and growth. We next performed a longer time course of Erk1/2 and Akt signaling in cells with or without junctions in the presence or absence of high Mtss1 (Figures 7b-e ). Confluent cells with junctions expressing high Mtss1 showed a modestly but consistently lower level of ERK1/2 phosphorylation than Scc9 controls (Figure 7b ). This effect was reversed in cells with disassembled cell-cell junctions or E-cadherin siRNA treatment, where Erk1/2 became rapidly phosphorylated in both Scc9 cells alone and Mtss1-GFP-expressing cells (Figure 7c and Supplementary Figure S3C ). Confluent cells with disrupted junctions (Figure 7c ) do not have as robust of an increase in pERK1/2 as subconfluent cells (Figure 3 ), suggesting that other factors likely contribute to the density-dependent inhibition of signaling in addition to adherence junctions. Further, in the absence of cell-cell junctions, we observed a reduction of the total EGFR degraded in Mtss1-GFP-expressing cells at both 90 and 120 min following EGF stimulation compared to Scc9 cells alone (Figure 7c ) in agreement with our findings in HeLa cells (Supplementary Figure S2) .
We also measured the activation of Akt following EGF stimulation in the presence or absence of cell-cell junctions as Akt activation is thought to drive invasion and metastasis (Irie et al., 2005) . We observe reduced Akt phosphorylation in Mtss1-overexpressing cells with cell-cell junctions over the period of a 120-min EGF stimulation (Figure 7d ). In the absence of cell-cell junctions or E-cadherin siRNA, Akt phosphorylation is delayed (Figure 7e and Supplementary Figure S3C ). Therefore, high Mtss1-expressing cells are more sensitive to cell-cell junction-induced inhibition of EGF signaling. Finally, as we observed dramatic effects on Akt activation, a signaling pathway that controls survival, we investigated the link between Mtss1 expression in HNSCC and sensitivity to EGFR chemotherapy (Figure 7f ). Mtss1 expression in Scc9 cells significantly increased the sensitivity to both Gefitinib and Erlotinib, two EGFR kinase inhibitors indicating a potential growth factor addiction in HNSCC-overexpressing Mtss1.
Discussion
Numerous chromosomal alterations result in the dysregulation of EGFR and other RTK signaling, which Figure 7 Cell-cell adherence junctions at least partly account for the density-dependent effects of Mtss1 on EGFR signaling. Scc9 cells were grown to confluence, starved overnight in Dulbecco's modified Eagle's medium (DMEM) or to disassemble cell-cell junctions in Ca 2 þ -free DMEM before EGF stimulation (25 ng/ml). (a) EGFR was immunoprecipitated and western blotted for total EGFR and EGFR tyrosine phosphorylation (4G10). Lysates were also prepared from a longer EGF stimulation time course and analyzed for Erk1/2 phosphorylation (pErk1/2), total EGFR and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (b, c) and Akt activation (pAkt) (d, e) and typical blots are shown. Below each western blot in (b-e) is quantification of Erk1/2 or Akt activation showing fold increase relative to Scc9 cells at 10 min EGF stimulation as determined by densitometry from four independent experiments. (f) Effect of Mtss1 expression in Scc9 cells on Gefitinib and Erlotinib treatment. Cells were assayed after 5 days growth with increasing drug concentrations and values were normalized to solvent control. Experiments were performed at least three times. For (b-e), *Po0.05. drives the development of HNSCC (Chung et al., 2006) . 8q23-24 contains genes encoding c-myc, FAK, autotaxin and Mtss1 (Hsia et al., 2003; Canel et al., 2006; Lin et al., 2006; Kelley et al., 2008) , making it an important amplification during tumor development. Mtss1 is a relatively uncharacterized member of this chromosomal region, and while Mtss1 has been widely shown to be lost during metastasis (Lee et al., 2002; Lin et al., 2005; Loberg et al., 2005; Parr and Jiang, 2009; Liu et al., 2010) , it is also overexpressed in the early stages of hepatocellular carcinoma and basal cell carcinoma (Callahan et al., 2004; Ma et al., 2007) .
Here we find that Mtss1 is overexpressed in primary HNSCC tumors and that Mtss1 regulates EGF signaling in two distinct ways depending on the cell density by regulating the localization of the EGFR to the plasma membrane. We show that this activity regulates cell proliferation and is beneficial for the initial growth of a tumor, but rapidly becomes detrimental to EGF signaling.
Mtss1 enhances EGF signaling at low cell density and in the absence of cell-cell junctions
We found that Mtss1 overexpression in HeLa and Scc9 HNSCC cells resulted in enhanced EGF signaling via elevated Erk1/2 phosphorylation to increase cell proliferation. In agreement with this, Mtss1 is a sonic hedgehog-responsive gene expressed during the development of basal cell carcinoma and enhances epidermal proliferation and invasive ingrowths (Callahan et al., 2004) .
The mechanism by which Mtss1 controls EGFR localization on the cell surface is not understood. Mtss1 is a member of the IMD family of proteins (also known as I-BAR) and the BAR domain family are critical regulators of membrane curvature in endocytosis (Machesky and Johnston, 2007) . Some parallels may exist with the metastasis suppressor CD82, a tetraspannin, which regulates the mobility of the EGFR on the plasma membrane and increases its recruitment to clathrincoated pits for internalization (Miranti, 2009; Danglot et al., 2010) . However, we did not find a significant change in the rate of internalization of biotinylated EGFR in Mtss1-overexpressing cells (Figure 2) , suggesting that altered receptor internalization is unlikely to explain our observations. High levels of Mtss1 increases surface EGFR levels and alter EGFR signaling. The EGFR signals only briefly from the plasma membrane, during the initial 10 min following EGF stimulation, before it is internalized via clathrin-mediated endocytosis (Sigismund et al., 2008) . We observe an enhancement of EGFinduced Erk1/2 phosphorylation at 10 min when the majority of the receptor is still on the plasma membrane (Sigismund et al., 2008) ; this is in contrast to the overexpression of cortactin in HNSCC, which acts further downstream to prolong endosomal signaling (Timpson, 2005 (Timpson, , 2007 . Further, high Mtss1-expressing cells in the absence of cell-cell junctions show a delayed phosphorylation of Akt (Figure 7) , which predominantly occurs on signaling endosomes (Mosesson et al., 2008) . Thus, at low densities, high Mtss1-expressing cells have upregulated EGFR signaling to Erk1/2, but delayed activation of Akt.
High cell density and cell-cell junctions inhibit Mtss1-mediated EGF signaling
In contrast to the enhancement of EGF signaling that Mtss1 confers at low cell densities, Mtss1 increases the inhibition of EGFR signaling at high cell densities when cells are making junctions (Figure 7 ). E-cadherin can recruit the EGFR to form a complex following the formation of cell-cell junctions (Qian et al., 2004; Bremm et al., 2008) . The E-cadherin/EGFR complex inhibits EGF signaling and mutation or loss of E-cadherin results in the reactivation of RTK signaling (Bremm et al., 2008) . We have shown that Mtss1 enhances EGFR plasma membrane localization (Figure 2) . Therefore, the EGFR may be sequestered away from Mtss1 by E-cadherin following the establishment of cell-cell junctions (Qian et al., 2004) . Interestingly, a mutant of E-cadherin lacking exon 8, D8 E-cadherin, that can still bind to EGFR, but has reduced cell-cell adhesion has enhanced localization of the EGFR to the cell surface and this also enhances EGF signaling (Bremm et al., 2008) .
Other metastasis suppressors, such as Nm23-H1, enhance cell-cell junctions to inhibit downstream targets of RTK signaling (Boissan et al., 2010) . Tiam1, a Racspecific guanine nucleotide exchange factor, important for the formation of cell-cell junctions, enhances primary tumor formation and inhibits metastasis (Uhlenbrock et al., 2004; Woodcock et al., 2009) . Lastly, EGFR signaling regulates cell-cell junction formation, suggesting the possibility that Mtss1-driven EGF signaling might directly enhance cell-cell junction formation (Betson et al., 2002) . High expression of Mtss1 enhances the formation of an epithelial-like layer in our organotypic assay, which is less proliferative than lower Mtss1-expressing Scc9 controls, further supporting the idea that high Mtss1 can enhance junction formation, epithelialization and quiescence at high cell densities. Finally, in vivo, high Mtss1 expression in xenograft tumors leads to increased keratinization and decreased proliferation in established tumors, supporting an inhibitory role of Mtss1 for proliferation of cells at high densities ( Figures 5 and 6 ).
Mtss1 as a marker of primary tumors for targeted chemotherapy The majority of studies involving Mtss1 have focused on metastatic cancer cells where expression is reduced or lost (Lee et al., 2002; Lin et al., 2005; Loberg et al., 2005; Parr and Jiang, 2009; Liu et al., 2010) . However, our data suggest that Mtss1 promotes the growth of HNSCC through enhanced EGF signaling, suggesting that Mtss1 may have a significant role in proliferation during the early stages of tumor development. Scc9, FaDu and Detroit 562 cells are well-differentiated HNSCC and express epithelial markers (E-cadherin and plakoglobin), but not mesenchymal markers (vimentin or N-cadherin) (Yang et al., 2008; Basu et al., 2010) . Chemotherapy of Scc9 xenografts leads to repopulation of the tumors with mesenchymal-like vimentin-positive Scc9 cells that are more resistant to chemotherapy due to a decrease in surface EGFR expression (Basu et al., 2010) .
We observe a more epithelial-like morphology of Scc9 cells overexpressing Mtss1, and an increase in the EGFR localization to the plasma membrane, which increases their sensitivity to the EGFR inhibitors Gefitinib and Erlotinib (Figure 7f ). Therefore, Mtss1 expression may serve as a useful patient stratification marker for tumors that are more susceptible to EGFR chemotherapy. However, Mtss1 is upregulated in FaDu and Detroit 562 HNSCC cell lines, which harbor several gene amplifications that enhance their proliferation, survival and resistance to chemotherapy (Timpson et al., 2005 (Timpson et al., , 2007 . For example, amplification of the c-Met receptor results in an alternative signaling pathway for Akt activation (Donev et al., 2011) . Under these circumstances, treatment with phosphoinositide 3-kinase inhibitors in combination with EGFR inhibitors is required to overcome c-Met amplification. We observe a poor induction of Akt phosphorylation in Mtss1-expressing cells (Figure 7 ) and potentially making Gefitinib or Erlotinib chemotherapy more effective (Figure 7e ). Therefore, Mtss1 amplification in isolation may control EGF signaling differently compared to when it is coamplified with other genes and further investigation is required.
Mtss1 as a regulator of metastasis Akt signaling, specifically Akt2, is required for epithelial-to-mesenchymal transition and invasion (Irie et al., 2005; Cheng et al., 2007) . Akt phosphorylation is either delayed or reduced in response to EGF stimulation when Mtss1 is present (Figure 7) and this is consistent with an anti-metastatic role for Mtss1. Interestingly, in prostate cancer cells, Erk inhibition is required for EGFR degradation, while Akt is required for EGF-mediated epithelial-to-mesenchymal transition and migration (Gan et al., 2010) . High Mtss1 expression confers enhanced Erk1/2 activation and reduced EGFR degradation (Figures 3 and 7) , but a reduced/delayed Akt activation. Basal cell carcinomas rarely metastasize, but Mtss1 expression in this situation can drive proliferation at the tumor periphery and local invasion of the surrounding tissue (Callahan et al., 2004 ) much like we observe here with Scc9 cells (Figures 5 and 6 ). We propose that Mtss1 is selectively beneficial for primary tumor initiation and may drive local invasion through proliferation in early tumor formation, but we saw no evidence of increased invasion in our Scc9 xenografts expressing Mtss1.
In conclusion, we have shown that Mtss1 enhances the surface expression of the EGFR, which results in enhanced Erk signaling and proliferation. However, with increasing cell density, we show that Mtss1 dampens EGF signaling, which inhibits proliferation in epithelial-like layers but not, critically, in small colonies of invading cells. We propose a simple model where Mtss1 is upregulated during the early stages of HNSCC (and hepatocellular carcinoma and basal cell carcinoma; Callahan et al., 2004; Ma et al., 2007) and is, mostly likely, driving proliferation through enhancing EGF signaling, although we cannot rule out the possible involvement of other RTK. Mtss1-driven proliferation, however, becomes inhibited as the cell density increases through the establishment of cell-cell junctions in a large primary tumor. Mtss1 is lost in metastatic cancers as it enhances cell-cell junction inhibition of EGF signaling that is required for cell motility and invasion through Akt.
Materials and methods
Western blotting and immunoprecipitation methods and a list of antibodies used are listed in Supplementary Methods.
All reagents were from Sigma-Aldrich (UK), unless otherwise stated. Cell culture reagents were from Gibco (Invitrogen, Paisley, Scotland). Mtss1 cDNA was cloned into the BamH1 and EcoR1 sites of pEGFP-N1 (Clontech, Mountain View, CA, USA) using standard molecular biology methods. Mtss1 short interfering RNA (siRNA) was from (Qiagen, Crawley, UK) (Hs_Mtss1_5, target sequence, 5 0 -CCGACGGATGTTC CAAGCCAA-3 0 ; E-cadherin, Hs_CDH1_13, target sequence, 5 0 -TCGGCCTGAAGTGACTCGTAA-3 0 ; Hs_CDH_12, target sequence, 5 0 -CTAGGTATTGTCTACTCTGAA-3 0 ). Statistical significance was calculated using an unpaired t-test, unless otherwise stated.
Cell lines and culture
The HNSCC cell lines (Scc9, FaDu and Detroit 562) were a kind gift from R Daly (Garvan Institute, Sydney, Australia). HeLa cells were from ATCC (Teddington, UK). All cell lines were maintained as described on the ATCC website and were authenticated using the Amp/STR identifier kit and results were analyzed using the Genemapper software version 4.0 (both from Applied Biosystems, Carlsbad, CA, USA). Stable Scc9 cells expressing Mtss1-GFP were selected in 0.5 mg/ml G418 and cultured as a mixed population. Cells were transfected with DNA and siRNA using Polyfect and Hyperfect (Qiagen) following the manufacturer's protocols. The organotypic invasion assay is described in Edward et al. (2005) and a brief description can be found in Supplementary Methods. For the clonogenic assay, 2000 cells per well of a six-well plate were seeded and cultured for 5 days. Cells were washed and labeled with Coomassie to visualize the colonies and the area of colony growth was calculated in ImageJ using the thresholding tool.
Animals and in vivo experiments
All animal procedures were carried out in accordance with UK Home Office regulations. Scc9 xenografts were made by injection of 2 Â 10 6 cells in 100 ml phosphate-buffered saline (PBS)/Matrigel (1:1) into the flanks of nude mice, using six animals per cohort. Tumors were measured with calipers at indicated times and animals were humanely killed at 6 weeks, where tumors were excised and processed for histology.
Surface biotinylation experiments
Cells were seeded at 3 Â 10 5 cells per well in a six-well plate and starved overnight in 0.1% normal growth media. Cells were stimulated with EGF and washed once with ice-cold PBS and incubated with 0.5 mg/ml EZ-Link Sulfo-NHS-Biotin (Pierce, Rockford, IL, USA, cat. no. 21326) in ice-cold PBS for 15 min to label the surface proteins. The reaction was quenched using 50 mM ammonium chloride/PBS and cells lysed in radioimmunoprecipitation buffer containing Halt protease inhibitors (Pierce) and phosphatase inhibitors (Roche phosphatase inhibitor cocktail II). Debris and insoluble material was removed by centrifugation at 12 000 g for 10 min and the supernatants were diluted to equal concentrations and 200 mg protein was incubated with 20 ml of NeutrAvidin beads (Pierce) to capture biotinylated proteins for 2 h. Beads were washed in lysis buffer three times and boiled in 2 Â sodium dodecyl sulfate-polyacrylamide gel electrophoresis sample buffer. Expression of EGFR and E-cadherin were analyzed in the surface and total cell lysate fractions.
FACS analysis
Scc9-and Mtss1-GFP-expressing Scc9 cells were incubated with PBS/EDTA to remove them from the tissue culture dishes. In total, 5 Â 10 5 cells were centrifuged and resuspended in 100 ml of 4% paraformaldehyde in PBS for 10 min to fix the cells. A measure of 1 ml of fluorescence-activated cell sorting (FACS) buffer (5% goat serum in PBS) was then added to the cells, followed by two washes in FACS buffer. Cells were then resuspended in 100 ml of primary antibody (mouse anti-EGFR) diluted 1:1000 in FACS buffer and incubated for 30 min. Cells were washed three times before incubating with Alex-594 anti-mouse secondary antibody (1:500) for 30 min. Finally, the cells were washed three times and resuspended in 1 ml of FACS buffer and analyzed using BD FACSAria (Oxford, UK). Unlabelled cells were used as a reference and 10 000 cells were analyzed for each condition.
Analysis of Mtss1 expression in primary HNSCC tumors
Affymetrix U133Plus2 CEL files of 71 HNSCCs and 14 normal epithelium samples were normalized and analyzed in the Partek Genomics Suite Software, version 6.5beta Copyright 2009. Robust multi-array analysis normalization and log 2 transformation of the data were followed by t-test, multiple test corrections of P-values (step-up) and Cox survival analysis. The cohort's clinical characteristics can be found in Thurlow et al. (2010) .
